Micheliolide alleviates ankylosing spondylitis (AS) by suppressing the activation of the NLRP3 inflammasome and maintaining the balance of Th1/Th2 via regulating the NF-κB signaling pathway

Zhong-Gu Tian¹#, Miaomiao Yao²#, Jie Chen³^*

¹Department of Orthopedics, Pinggu Hospital, Beijing Hospital of Traditional Chinese Medicine, Beijing, China; ²Drug Clinical Trial Institution, Xi’an Gaoxin Hospital, Xi’an, China; ³Department of Osteoporosis, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, China

Contributions: (I) Conception and design: All authors; (II) Administrative support: J Chen; (III) Provision of study materials or patients: ZG Tian, M Yao; (IV) Collection and assembly of data: ZG Tian, M Yao; (V) Data analysis and interpretation: ZG Tian, M Yao; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

#These authors contributed equally to this work.

Correspondence to: Jie Chen. Department of Osteoporosis, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, China. Email: chenjielz@163.com.

Background: Ankylosing spondylitis (AS) is a common form of inflammatory arthritis. Micheliolide (MCL), a sesquiterpene lactone, is reportedly involved in the alleviation of inflammatory response. This study aimed to investigate the mechanism of MCL in the treatment of AS.

Methods: Mice were randomly divided into five groups: the sham group, the MCL (50 mg/kg) group, the AS model group, the AS + MCL (20 mg/kg) group, and the AS + MCL (50 mg/kg) group. After the addition of the inhibitor celastrol, mice were randomly divided into five groups: the sham group, the AS model group, the AS + MCL (50 mg/kg) group, the AS + Celastrol (1 mg/kg) group, and the AS + Celastrol (1 mg/kg) + MCL (50 mg/kg) group.

Results: Compared with the AS model mice, the protein expression levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and IL-18 were decreased after MCL treatment. The protein expression levels of caspase-1 p10, IL-1β p17, NOD-like receptor family and pyrin domain containing 3 (NLRP3), caspase-1, and apoptosis-associated speck-like protein (ASC) were also reduced. The protein expression levels of Interferon (IFN)-γ were down-regulated, but levels of IL-4 were increased. Western blotting and immunohistochemistry revealed that the levels of p-IκB α were up-regulated, while the levels of phosphorylated-p65 were down-regulated. After the addition of celestrol, MCL treatment significantly reduced the levels of p-p65, NLRP3, caspase-1, and ASC. Meanwhile, the levels of IFN-γ were markedly down-regulated, but the levels of IL-4 were enhanced.

Conclusions: Our study found that MCL suppressed the activation of NLRP3 inflammasome and maintained the balance of Th1/Th2 via regulating NF-κB signaling. Therefore, MCL could potentially be used to treat AS.

Keywords: Micheliolide; ankylosing spondylitis (AS); NOD-like receptor family and pyrin domain containing 3 (NLRP3); Th1/Th2; nuclear factor-kappa B (NF-κB)

doi: 10.21037/atm-20-4987
View this article at: http://dx.doi.org/10.21037/atm-20-4987

^ ORCID: 0000-0003-3943-9195.
Introduction

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease. Patients with AS often experience sacroiliitis and inflammatory changes of the axial skeleton, and develop syndesmophytes and bony ankylosis of the spine (1). One study has shown that the prevalence of AS in the United States increases from 0.04% to 0.09% between 2006 and 2016, with the mean age of patients range from 49.52 to 50.00 years old in the same period. Between 2006 and 2016, the proportion of AS patients who are women rose from 40% to over 47% (2). A variety of genetic and environmental factors are linked to the pathogenesis of AS (3). Moreover, the body’s ability to negatively regulate immune response is impaired with AS, and this might also be related to its etiology (4).

Micheliolide (MCL), a guaianolide sesquiterpene lactone, is derived from *Michelia compressa* and *Michelia champaca* and can also be in vitro synthesized from parthenolide (5). Previous research has shown that MCL exerts an inhibitive effect on lipopolysaccharide (LPS)-induced inflammatory response and can protect mice from LPS challenge through the nuclear factor-kappa B (NF-κB) and phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT) pathways (6). Research has also demonstrated that in *mycobacterium tuberculosis*, MCL plays an anti-inflammatory role by down-regulating NLRP3 inflammasome activation via the PI3K/Akt/NF-κB pathway (7). Moreover, MCL alleviates hepatic steatosis through the inhibition of inflammation and promotion of autophagy (8). Furthermore, MCL inhibits NF-κB activation, and attenuates carcinogenesis in AOM/DSS-induced colorectal cancer (CRC) (9). Based on these encouraging findings, we speculated that MCL might play a protective role in AS in mice and subsequently designed this study to test our hypothesis. Therefore, this study aimed to investigate the mechanism of MCL in the treatment of AS.

We present the following article in accordance with the ARRIVE reporting checklist (available at http://dx.doi.org/10.21037/atm-20-4987).

Methods

**AS model**

All animal experiments were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals and received approval from the Ethics Committee of Beijing Hospital of Traditional Chinese Medicine. Specific-pathogen-free (SPF) BALB/c mice aged 5–6 weeks old, were obtained from the Beijing Weitonglihua Experimental Animal Technology Co., Ltd. The mice were housed in a controlled environment at 25±3℃, humidity 60%, under a 12-h light/dark cycle with free access to water. Mice were randomly divided into five groups: the sham group, the MCL (50 mg/kg) group, the AS model group, the AS + MCL (20 mg/kg) group, and the AS + MCL (50 mg/kg) group. After the addition of the inhibitor celastrol, mice were randomly divided into five groups: the sham group, the AS model group, the AS + MCL (50 mg/kg) group, the AS + Celastrol (1 mg/kg) group, and the AS + Celastrol (1 mg/kg) + MCL (50 mg/kg) group.

Proteoglycan lyophilized powder was dissolved in 1× phosphate buffer saline (PBS) (pH =7.4) to a concentration of 10 mg/mL on ice. Dimethyloctadecyl ammonium bromide (DDA) was selected as the immunoadjuvant and was dissolved in 1× PBS (pH =7.4) to a concentration is 20 mg/mL on ice. Then, 100 μL of proteoglycan solution and DDA solution was mixed well. Female BALB/c mice were intraperitoneally injected with 200 μL of mixed solution (10) to establish the AS mouse model. An equivalent volume of PBS was administered to the model and normal control mice.

MCL was supplied by Accendatech Co., Ltd. (Tianjin, China) and was prepared daily by being fully dissolved in normal saline solution. The model and normal control group mice were given an equivalent volume of saline solution each day. Each group of mice was treated for 16 weeks. The mice were given daily injections of Celastrol at a dose of 1 mg/kg (11).

**Cytokine enzyme-linked immunosorbent assay (ELISA)**

Samples of peripheral blood were collected from the AS model mice and the serum was separated. The TNF-α, IL-6, IL-1β, IL-18, IFN-γ, and IL-4 levels in the serum were detected, according to the protocol of the manufacturer. A Bio-Rad Microplate reader (CA, USA) was used to determine the optical density, and absorption was measured at 450 nm. A cytokine standard supplied with the ELISA kit was used to establish a standard curve for each measurement.

**Flow cytometry analysis**

Peripheral blood mononuclear cells (PBMCs) were collected from the AS mice for flow cytometry. The PBMCs were added to a tube containing antibody and dyeliquor, and
incubated for 15 min in darkness. Then, 2 mL 1x Lysing Solution was added and the samples were incubated for a further 30 min in darkness, before centrifugation at 1,500 rpm and removal of the supernatant. Subsequently, 2 mL PBS was added, and the samples were centrifuged at 1,500 rpm and the supernatant was removed. Finally, 500 μL PBS was added. Analysis of the samples was performed with a FACS Aria cell sorter (BD Biosciences), and FlowJo (Tree Star, OR) was used to analyze the data.

Western blot

PBMCs were lysed with 200 μL of radioimmunoprecipitation assay (RIPA) buffer (Thermo Scientific, USA) containing protease inhibitor (Roche, Germany). Then, 50 μg of total protein was loaded into 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer, and the proteins were transferred to polyvinylidene difluoride (PVDF) membranes. After sealing with 5% skimmed milk at 37 °C for 120 min, the PVDF membranes were incubated at 4 °C overnight with the primary antibodies against capase-1 p10 (Abcam, 1:1,000), IL-1β p17 (R&D Systems, Minneapolis, MN, USA; 1:1,000), NLRP3 (Cell Signaling, 1:1,000), caspase-1 (Cell Signaling, 1:1,000), ASC (Cell Signaling, 1:1,000), p-p65 (Cell Signaling, 1:1,000), and p-IκB α (Cell Signaling, 1:1,000) or Lamin-B (Cell Signaling, 1:1,000). Following that, the membranes were incubated with goat anti-rabbit IgG horseradish peroxidase (HRP)-conjugated secondary antibodies at 37 °C for 60 min. An automatic digital gel image analysis system Bio-Rad CFX-96 (Bio-Rad, CA, USA) was employed to determine and analyze the band densities.

Immunohistochemistry

PBMCs were incubated overnight with primary antibodies against p65 (Cell Signaling, 1:800). The corresponding secondary antibodies were incubated at room temperature for 1 h. An Olympus DX51 fluorescence microscope (Olympus, Tokyo, Japan) was used to observe the cells. Data analysis was performed with Image 6.0 (Media Cybernetics, USA).

Statistical analyses

All experiments were independent and were carried out at least in triplicate. Experimental data were presented as the mean ± standard deviation (SD). Statistical analyses were performed using SPSS 22.0 software (SPSS Inc., Chicago, IL, USA). Student's t-test was used to compare the groups. Differences between groups were compared using one-way analysis of variance (ANOVA), and Duncan’s method was used as a post-hoc test. P<0.05 was considered to be statistically significant, and differences were considered significant at P<0.05.

Results

MCL alleviated the levels of TNF-α, IL-1β, IL-6, and IL-18 in the AS model

Previous research has indicated that the levels of TNF-α, IL-1β, and IL-6 are distinctly up-regulated in AS patients, making them attractive therapeutic targets (12). The result of ELISA revealed that the protein expressive levels of TNF-α, IL-1β, IL-6, and IL-18 were increased in the AS model mice compared to the sham group (P<0.05) (Figure 1). Following MCL treatment, the levels of TNF-α, IL-1β, IL-6, and IL-18 were decreased compared with the AS model mice, especially in the high concentration group (P<0.05). These findings suggested that MCL had an alleviative effect on inflammatory response in the AS model.

MCL alleviated the levels of Caspase1 p10, IL1β p17, NLRP3, caspase-1, and ASC in the AS model

One previous study has reported the possible involvement of the NLRP3 inflammasome in the pathogenesis of AS, which means it can potentially be a therapeutic target in AS treatment (1). In accordance with these results, we found that the protein expression levels of caspase-1 p10, IL1β p17, NLRP3, caspase-1, and ASC in the AS model mice were notably higher than in the sham group mice (Figure 2) (P<0.05). However, the levels of caspase-1 p10, IL1β p17, NLRP3, caspase-1, and ASC were decreased after MCL treatment (P<0.05). The protein expression levels of caspase1 p10, IL1β p17, NLRP3, caspase-1, and ASC were not significantly different between the MCL (50 mg/kg) group and the sham group (Figure 2) (P>0.05). These results suggested that MCL could suppress the activation of the NLRP3 inflammasome in the AS model.

MCL down-regulated IFN-γ levels and up-regulated IL-4 levels in AS model

Imbalance in the levels of Th1 and Th2-secreted cytokines
may be critical to the development of autoimmune diseases (13). Remarkably, elevated levels of Th1 cytokines and reduced levels of Th2 cytokines in the peripheral blood of patients with AS can indicate disease activity (14). The levels of IFN-γ and IL-4 were detected by ELISA and flow cytometry, respectively. As shown Figure 3, the result of ELISA demonstrated that the levels of IFN-γ were markedly enhanced in AS model group compared with the sham group (P<0.05). Meanwhile, the levels of IL-4 were markedly inhibited (P<0.05). However, the levels of IFN-γ were significantly down-regulated after treatment with MCL in contrast with that in the AS model group, while the levels of IL-4 were markedly up-regulated (P<0.05). The result of flow cytometry was consistent with the findings of ELISA. These results suggested that MCL can adjust the balance of Th1/Th2 in the AS model.

**MCL down-regulated p-p65 levels and up-regulated p-IκB α levels in AS model**

In mammals, the NF-κB signaling pathway mainly involves the p65/p50 heterodimer (15). The essential role of NF-κB signaling in the progression of AS, rheumatoid arthritis, and different cancers has been described previously (16-18). As Figure 4 shows, the protein levels of p-p65 were increased, while the levels p-IκB α were decreased in AS model group compared with those sham group. After treatment with MCL, the levels of p-p65 were decreased (P<0.05), but the levels of p-IκB α were increased (P<0.05). At the same time, the result of immunohistochemistry showed that the percentage of p65-positive rate also were notably lower after MCL treatment (P<0.05). These findings indicated that MCL might play a protective role in mice with AS via regulating the NF-κB signaling pathway.

**MCL alleviated activation of the NLRP3 inflammasome and maintained the balance of Th1/Th2 via regulating the NF-κB signaling pathway**

To further demonstrate whether MCL played a role in regulating the NF-κB signaling pathway in the AS, we added celastrol to inhibit the NF-κB pathway and explore
the function of MCL in AS model mice. Celastrol, an NF-κB inhibitor, was found to ameliorate hypercalciuria and articular cartilage lesions in a secondary osteoporosis mouse model (11). As shown in Figure 5, the protein expression levels of p-p65, NLRP3, caspase-1, and ASC were lower in the group with inhibitor than in the AS model mice (P<0.05). Interestingly, following intervention with MCL, the protein expression levels of p-p65, NLRP3, caspase-1, and ASC were lower than in the group with inhibitor (P<0.05). At the same time, the levels of IFN-γ in the inhibitor group were significantly repressed in contrast with those in the AS model group, while the levels of IL-4 were markedly elevated (P<0.05). Furthermore, after intervention with MCL, the levels of IFN-γ were more significantly repressed compared with the inhibitor group, while the levels of IL-4 were more markedly elevated. These results suggested that MCL could alleviate AS through suppressing the activation of the NLRP3 inflammasome and maintaining the balance...
of Th1/Th2 via the regulation of the NF-κB signaling pathway in our AS model.

**Discussion**

Ankylosing spondylitis (AS) is a common form of inflammatory arthritis. Wang et al. (19) has found that the levels of IL-23 and IL-17 are elevated in serum collected from patients with active AS. Further, IL-17 has been shown to enhance T-cell activation and stimulate a variety of cells (fibroblasts, endothelial and epithelial cells, and macrophages) to produce proinflammatory mediators [interleukin-1β (IL-1β), IL-6, TNF-α, and chemokines] (20). Previous research has indicated that TNF-α, IL-1β, and IL-6 are distinctly up-regulated in AS patients (12). More importantly, MCL reduces the secretion of IL-6, TNF-α, IL-1β, MCP-1, IFN-β and IL-10 in sera, and ameliorates lung and liver damage (6). In this study, the AS model mice showed the expression levels of TNF-α, IL-1β, and IL-6 were significantly elevated. Meanwhile, we found the expressions levels of TNF-α, IL-1β, IL-6, and IL-18 were decreased in the AS model mice after intervention with MCL.

NOD-like receptor family and pyrin domain containing 3 (NLRP3) inflammasome activity is central to the development of various inflammatory diseases. Both adapter protein ASC and pro-caspase-1 are activated by NLRP3 inflammasome, which leads to caspase-1 activation. Subsequently, interleukin-1β (IL-1β), IL-18, or high mobility group box-1 protein (HMGB1) are secreted to exert a regulating effect (21,22). Research has indicated that NLRP3 inflammasome is associated with susceptibility to AS (23). Interestingly, MCL plays an important role in modulating *Mycobacterium tuberculosis* (Mtb)-induced
inflammatory response through down-regulating the activation of NLRP3 inflammasome (7). The result of this article showed that the levels of capase-1 p10, IL-1β p17, NLRP3, caspase-1, and ASC in AS model mice were notably higher. Remarkably, the levels of capase-1 p10, IL-1β p17, NLRP3, caspase-1, and ASC were decreased following MCL treatment. These results suggested that MCL could alleviate AS by suppressing the activation of the NLRP3 inflammasome.

CD4+ T cells, and their subsets including Th1, Th2 and Th17, regulatory T cells, follicular helper T cells, and Th9, have multiple functions (24). Interferon-γ (IFN-γ) is known to be a Th1 cytokine and is the only type II interferon. Recently, abnormal expression of IFN-γ has been reported to be associated with a variety of auto-inflammatory and immune diseases (25,26). The Th1-secreted cytokine IFN-γ antagonizes the secretion of Th2 cytokines IL-4 and IL-10, thereby inhibiting Th2 response (27). Previous research has showed that the expression profile of IFN-γ has an obvious association with rs2430561 polymorphism, suggesting that rs2430561 minor allele may regulate the expression of IFN-γ, thus contributing to AS risk (28). According to previous research, IL-4 attenuates the pathogenesis of AS via modulating macrophage polarization (29). This study revealed that the levels of IFN-γ were markedly enhanced, while the levels of IL-4 were markedly inhibited. However, the levels of IFN-γ were suppressed whereas the levels of IL-4 were increased following MCL treatment. In methicillin-resistant S. aureus (MRSA) infection mouse model, MCL down-regulated the expression of IL-6, TNF-α, MCP-1/CCL2 and IFN-γ in sera, and ameliorated the organ damage of liver and kidney (30). These results suggested that MCL could adjust the balance of Th1/Th2.

NF-κB, a ubiquitous family of transcription factors, is involved in a variety of essential processes in the body including inflammation, immunity, and cell proliferation.

Figure 4 MCL down-regulated the level of p-p65 and up-regulated that of p-IκB α in the AS model. (A) The protein expression levels of p-p65 and p-IκB α were detected by Western blot. Semi-quantitative analysis of the relative levels of p-p65 and p-IκB α in each group of mice was performed. (B) The protein expression of p65 was detected by immunohistochemical staining. Magnification 200×. Semi-quantitative analysis of the relative amounts of p65 in each group of mice was performed. The results are presented as mean ± SD and represent three individual experiments. **, P<0.01 versus sham group; *, P<0.05; #, P<0.01 versus AS model group.
and survival (31). AS is a common autoimmune disease, and its pathogenesis is closely related to immune function (32). The genetically determines high activity of the tumor necrosis factor-α (TNF-α), IL-23/IL-17, and NF-κB pathways increases the risk of AS (33). MCL attenuates the inflammatory responses and lipid accumulation in lipid mixture (LM)-treated AML12 and L02 cells by up-regulating PPAR-γ and decreasing p-IκBα and p-NF-κB/p65 (8). MCL suppresses LPS-stimulated the activation of IκBα/NF-κB pathway and Akt pathway (34). In our study, the levels of p-p65 were notably elevated, while the levels of p-IκBα were decreased in the AS mouse model. Interestingly, after treatment with MCL, the levels of p-p65 were notably decreased, while the levels of p-IκBα were increased. These results suggested that MCL could inhibit the activation of the NF-κB pathway.

To further demonstrate whether MCL played a role in regulating the NF-κB signaling pathway in the AS, we added celastrol to inhibit the NF-κB pathway and explore the function of MCL in AS model mice. Celastrol, an NF-κB inhibitor, was found to ameliorate hypercalciuria and articular cartilage lesions in a secondary osteoporosis mouse model (11). Celastrol significantly inhibits cell proliferation of isolated AS fibroblasts and in vitro osteogenic differentiation (35). Curcubitor A (CA) effectively down-regulates the expression of NF-κB/NLRP3 pathway on adjuvant arthritis (AA) rats (36). Epigallocatechin gallate maintains the Th1/Th2 balance and suppresses immunoinflammatory response in colonic tissue through the TLR4/MyD88/NF-κB signaling pathway (37). The anti-inflammatory mechanism of citrus tachibana leaves ethanol extract (CTLE) may involve the modulation of Th1/Th2 imbalance via inhibition of NF-κB signaling and histamine secretion (38). In the research, after intervention with MCL, the protein expression levels of p-p65, NLRP3, caspase-1 and ASC were lower than in the inhibitor group. The levels of IFN-γ were more significantly repressed compared with the inhibitor group, while the levels of IL-4 were more markedly elevated. These results suggested that MCL alleviated AS via regulating the NF-κB signaling pathway.
pathway.
In summary, MCL inhibited TNF-α, IL-1β, IL-6, and IL-18 expression, and reduced the protein expression levels of caspase-1 p10, IL-1β p17, NLRP3, caspase-3, and ASC. It also suppressed the expression of IFN-γ but increased that of IL-4. In addition, the levels of p-p65 were decreased, while the levels of p-IκBα were increased. MCL alleviated AS by suppressing the activation of the NLRP3 inflammasome and maintaining the balance of Th1/Th2 via regulation of the NF-κB signaling pathway.

Acknowledgments
This article thanks Beijing Hospital of Traditional Chinese Medicine, Xi’an Gaoxin Hospital, and Gansu Provincial Hospital of Traditional Chinese Medicine for its support.

Funding: None.

Footnote
Reporting Checklist: The authors have completed the ARRIVE reporting checklist. Available at http://dx.doi.org/10.21037/atm-20-4987

Data Sharing Statement: Available at http://dx.doi.org/10.21037/atm-20-4987

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-4987). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All animal experiments were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals and received approval from the Ethics Committee of Beijing Hospital of Traditional Chinese Medicine (approval ID: No. 20190320).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References
12. Tärner IH, Müller-Ladner U, Uhlemann C, et al. The
effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol 2009;28:397-402.


33. Sode J, Bank S. Genetically determined high activities of the TNF-alpha, IL23/IL17, and NFkB pathways were associated with increased risk of ankylosing spondylitis. BMC Med Genet 2018;19:165.


37. Bing X, Xuelei L, Wanwei D, et al. EGCG Maintains Th1/Th2 Balance and Mitigates Ulcerative Colitis Induced


(English Language Editor: J. Reynolds)

Cite this article as: Tian ZG, Yao M, Chen J. Micheliolide alleviates ankylosing spondylitis (AS) by suppressing the activation of the NLRP3 inflammasome and maintaining the balance of Th1/Th2 via regulating the NF-κB signaling pathway. Ann Transl Med 2020;8(16):991. doi: 10.21037/atm-20-4987